{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05416554",
            "orgStudyIdInfo": {
                "id": "IRB-56813"
            },
            "secondaryIdInfos": [
                {
                    "id": "CCT5069",
                    "type": "OTHER",
                    "domain": "OnCore"
                }
            ],
            "organization": {
                "fullName": "Stanford University",
                "class": "OTHER"
            },
            "briefTitle": "Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford",
            "officialTitle": "Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford - A Pilot Study",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "long-term-cognitive-neuropsychiatric-and-functional-outcomes-in-adults-who-have-received-chimeric-antigen-receptor-t-cell-car-t-therapy-for-aggressive-lymphoma-at-stanford"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-05-20",
            "studyFirstSubmitQcDate": "2022-06-08",
            "studyFirstPostDateStruct": {
                "date": "2022-06-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-09",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Stanford University",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study aims to assess the feasibility of performing neuropsychological testing to measure the cognitive performance of individuals following Axicabtagene ciloleucel CAR-T therapy at Stanford."
        },
        "conditionsModule": {
            "conditions": [
                "Non Hodgkin Lymphoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "SUPPORTIVE_CARE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Neuropsychological testing",
                    "type": "OTHER",
                    "description": "Participants will take neuropsychological testing in-person or via telehealth video",
                    "interventionNames": [
                        "Behavioral: Neuropsychological testing"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BEHAVIORAL",
                    "name": "Neuropsychological testing",
                    "description": "Upon completion of the consent, the subject will be booked into an available 90 minute in-person or remote neuropsychological testing",
                    "armGroupLabels": [
                        "Neuropsychological testing"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of patients who complete neuropsychological testing in the post-CAR-T adult population",
                    "timeFrame": "6 months"
                },
                {
                    "measure": "Number of patients who complete telehealth neuropsychological testing in the post-CAR-T adult",
                    "timeFrame": "6 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Wechsler Test of Adult Reading WTAR Neuropsychological testing",
                    "description": "The neuropsychological testing will capture any potential deficits in language, processing speed, executive functioning and visuospatial abilities, and may be compared to age and education-matched normative data.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Hopkins Verbal Learning Test HVLT",
                    "description": "The neuropsychological testing will capture any potential deficits in language, processing speed, executive functioning and visuospatial abilities, and may be compared to age and education-matched normative data.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Controlled Oral Work Association Test COWAT",
                    "description": "The neuropsychological testing will capture any potential deficits in language, processing speed, executive functioning and visuospatial abilities, and may be compared to age and education-matched normative data.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Trails A and B (Oral Trails)",
                    "description": "The neuropsychological testing will capture any potential deficits in language, processing speed, executive functioning and visuospatial abilities, and may be compared to age and education-matched normative data.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Digit Span",
                    "description": "The neuropsychological testing will capture any potential deficits in language, processing speed, executive functioning and visuospatial abilities, and may be compared to age and education-matched normative data.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Clock Drawing Test",
                    "description": "The neuropsychological testing will capture any potential deficits in language, processing speed, executive functioning and visuospatial abilities, and may be compared to age and education-matched normative data.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Short form of Quality of Life SF-36",
                    "description": "Items from the SF36 (Short Form 36) survey",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "General Anxiety Disorder Assessment GAD-7",
                    "description": "Assesses anxiety symptoms\n\nThe following cut-offs correlate with level of anxiety severity:\n\nScore 0-4: Minimal Anxiety, Score 5-9: Mild Anxiety, Score 10-14: Moderate Anxiety, Score greater than 15: Severe Anxiety",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Patient Health Questionnaire PHQ9",
                    "description": "Assesses depressive symptoms PHQ-9 Score 0 - 4 None, Mild= 5 - 9 , Moderate=10 - 14 , Moderately Severe=15 - 19 , Severe=20 - 27",
                    "timeFrame": "Baseline"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* \\>/= 18 years-old\n* Treated with Axicabtagene ciloleucel CAR-T therapy at Stanford Or\n* Treated with standard commercial Axicabtagene ciloleucel CAR-T therapy elsewhere and followed primarily by SHC Blood and Bone Marrow transplant providers\n* \\>/= 6 months from the date of CAR-T infusion\n* Fluent in English\n* Able to attend and participate in in-person testing (Arm I)\n* Able to participate in remote video testing with adequate workspace, computer and internet capabilities for a reliable telehealth video connection (Arm II)\n\nExclusion Criteria:\n\n* Concurrent enrollment in a CAR-T therapeutics research study\n* Unable to be present for the scheduled testing\n* Unable to participate in testing due to severe cognitive or physical limitation\n* Actively receiving chemotherapy\n* Progressive cancer",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Brian J Scott, MD",
                    "role": "CONTACT",
                    "phone": "(650) 723-6409",
                    "email": "bjscott@stanford.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Brian Scott, MD",
                    "affiliation": "Stanford University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Stanford Cancer Center",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94305",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Brian J Scott, MD",
                            "role": "CONTACT",
                            "phone": "bjscott@stanford.edu",
                            "email": "bjscott@stanford.edu"
                        },
                        {
                            "name": "Michelle Monje, MD, PhD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Gayle Deutsch, PhD, ABPP",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Matthew J Frank, MD, PhD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Sheila Lahijani, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Tracy P Murray, MSN, RN, AGACNP-BC",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3724",
                    "name": "Aggression",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}